Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis?
Level 5 - mechanism / opinion, no new human data
In vitro laboratory study and mechanistic reasoning without clinical trial data
PubMed 78322 · doi:10.1016/s0140-6736(78)91505-2
What was done
Researchers examined the effect of eicosapentaenoic acid (EPA) compared to arachidonic acid (AA) on platelet aggregation in human platelet-rich plasma in vitro, and investigated whether vessel walls could utilize EPA to produce anti-aggregating prostaglandins.
What was found
No quantitative data or exact numbers are reported in the abstract. Qualitatively, EPA did not induce platelet aggregation in human platelet-rich plasma (likely due to inactive thromboxane A3 formation), and vessel wall tissue used EPA to produce an anti-aggregating substance (likely delta17-prostacyclin).
Why it matters
This paper proposed an early biochemical mechanism to explain how dietary omega-3 fatty acids might induce an antithrombotic state, offering a biological rationale for lower myocardial infarction rates observed in populations with high-EPA diets.
Limits
The study is limited to in vitro bench observations and mechanistic hypothesis generation. The abstract reports no sample sizes, numerical measurements, statistical comparisons, or in vivo clinical outcome data.
Cited by
- supports Dyerberg and colleagues published a paper in 1978 proposing that EPA reduced platelet stickiness in Greenland Inuits, conferring protection against atherothrombosis.